Exercise of Warrants and Issue of Shares

RNS Number : 9250S

Advanced Oncotherapy PLC

14 July 2015

 

14 July 2015       

Advanced Oncotherapy plc

("AVO" or the "Company")

Exercise of Warrants and Issue of Shares

Issue of Shares

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has today issued 600,000 new ordinary shares ("New Ordinary Shares") of 1p in the Company at a subscription price of 8 pence per Ordinary Share (being the closing mid price on 13 July 2015) to Dr Enrico Vanni, a non-executive director, in lieu of his non-executive director fee and fees in connection with his providing operational management support to the Company's ADAM subsidiary.

Following this transaction, Dr Vanni now holds 13,050,000 Ordinary Shares representing 0.97% of the issued share capital of the Company.

Exercise of Warrants and Issue of Shares

The company further announces that it has today issued 16,400 new ordinary shares ("Further Shares") of 1p in the Company at a price of 6 pence per Further Share pursuant to the exercise of warrants.

Admission

Application has been made for the 600,000 New Ordinary Shares and the 16,400 Further Shares (together "Shares") to be admitted to trading on AIM ("Admission") and it is expected that Admission will occur on 21 July 2015. The Shares will rank pari passu in all respect with the existing Shares of the Company.

Total voting rights

Following Admission, the Company's enlarged issued share capital will comprise 1,377,039,026 Shares, with voting rights. The Company does not hold any Shares in treasury. Therefore the total number of Shares in the Company with voting rights will be 1,377,039,026. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Advanced Oncotherapy Plc	www.avoplc.com
Sanjeev Pandya, CEO	Tel: [phone]
Nicolas Serandour, CFO
Westhouse Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten	Tel: [phone]
Beaufort Securities (Joint Broker)
Saif Janjua / Jon Levinson	Tel: [phone]
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects. Therefore, the disruptive technology of the Company changes the financial model of proton therapy now that LIGHT is expected to have a comparable cost to conventional radiotherapy.

The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

MSCRJMRTMBMBBRA